Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features

(2009) C. Haferlach et al.   BLOOD

Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

(2008) M. A. Sanz et al.   BLOOD

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated

(2008) S. Lugthart et al.   BLOOD

Monitoring minimal residual disease in acute myeloid leukaemia withNPM1mutations by quantitative PCR: clonal evolution is a limiting factor

(2008) Christina Papadaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia

(2008) B. Falini et al.   HAEMATOLOGICA

Cytogenetically Normal Acute Myeloid Leukemia

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE